Regulus has bulked up its pipeline with two new drug candidates due to start trials next year, as it tries to get lead hep C candidate back on track.

Neurimmune and TVM Capital Life Science have partnered to create and fund a single-asset biotech focused on amyotrophic lateral sclerosis.

TiGenix is aiming to net $42.9 million in a Nasdaq IPO, approximately half of which will go toward a U.S. late-phase trial of Crohn's disease candidate…

After a torrid year that has seen multiple deaths in testing, FDA- and self-imposed study halts and its shares tanking, Juno last night held up to the light…

John Jenkins is retiring from the FDA's office for new drugs next year, with Janet Woodcock set to run the office in the interim.

British biotech ReNeuron has posted generally encouraging midstage data which showed their stem cell therapy could help certain stroke patients move their arms…

Agios Pharmaceuticals has moved closer to starting a pivotal clinical trial of one of its wholly owned treatments for pyruvate kinase deficiency.

Despite looking to have taken a big step back from cell therapy work this year, Novartis hopes to be first to market a new CAR-T med as it plans to file early…

R&D